- Home
- VRDN vs SGRY Comparison
VRDN vs SGRY Comparison
Compare VRDN & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRDN | SGRY |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VRDN | SGRY |
|---|---|---|
| Price | $16.89 | $14.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $35.46 | $22.25 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.14 |
| EPS | N/A | ★ N/A |
| Revenue | $5,706,000.00 | ★ $1,145,438,000.00 |
| Revenue This Year | $13.73 | $5.09 |
| Revenue Next Year | $279.00 | $5.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.07 | $11.41 |
| 52 Week High | $34.29 | $24.10 |
Technical Indicators
Market Signals| Indicator | VRDN | SGRY |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 51.63 |
| Support Level | $15.68 | $13.33 |
| Resistance Level | $19.54 | $16.15 |
| Average True Range (ATR) | 0.86 | 0.70 |
| MACD | 0.79 | -0.06 |
| Stochastic Oscillator | 54.11 | 34.27 |
Price Performance
Historical ComparisonAbout VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.